Kevin Honeycutt was named CEO and president of Alliance for Cancer Gene Therapy in December 2018 and elected to its board of directors in June 2022. As chief executive officer, Mr. Honeycutt’s role is to help realize and enhance the vision of ACGT’s co-founders, Barbara Netter and her late husband Edward, by focusing the organization on solving the next generation of challenges brought by metastatic cancers while continuing to build organizational alliances and joint ventures.

Prior to joining ACGT, Mr. Honeycutt served as president of the Avon Breast Cancer Crusade and executive director of the Avon Foundation for Women. Through his consulting firm, Honeycutt Partners, he served in a variety of roles helping lead major projects for the American Diabetes Association, the New Venture Fund, the Entertainment Industry Foundation, the United Cancer Front, the San Francisco AIDS Foundation and other leading nonprofit organizations.

Mr. Honeycutt currently serves on the Board of Directors of the Global Cancer Institute and Friends of Mozart and is a member of the National Council of the Eastman School of Music at the University of Rochester. He is a past Board member of the Jonsson Cancer Center Foundation at the University of California, Los Angeles.